Are repaglinide tablets any side effects and will there be any adverse reactions

Hello, it's *** as follows:

As with other oral hypoglycemic drugs, repaglinide may cause changes in blood sugar, such as hyperglycemia and hypoglycemia. As with every type of diabetes**, the occurrence of these reactions depends on individual factors such as diet, dosage, exercise and stress response. The clinical application of repaglinide and other hypoglycemic drugs has shown that the following adverse reactions may occur when taking repaglinide:

According to the incidence of adverse reactions, they are defined as follows: Rare adverse reactions: the incidence rate is 1 10000 and 1 1000.

Very rare adverse reactions: incidence 1 10000. 1.

Immune system disorders Allergic reactions Allergic reactions, such as itching, redness, and hives, can occur. Very rarely, widespread allergic reactions or immune reactions such as vasculitis occur. 2.

Metabolic and nutritional disorders Hyperglycemia.

Hope it helps.

Repaglitinide tablets are commonly used for diabetes mellitus and are generally used for diabetic patients who have high blood sugar after diet control and exercise.

Generally, it can be taken at the same time as metformin sustained-release tablets, and blood sugar needs to be checked regularly during the period of taking, and the adverse reactions are related to the individual's physical constitution and will not be affected.

Hello, *** is very small. There are several categories of oral drugs, the half-life of each drug, the duration of the drug, are different, each has its own drug characteristics, want to find the right for their own condition, you need to go to the diabetes hospital for a detailed examination, under the guidance of experienced doctors, in order to find a suitable drug program for your condition, but also to set a diet plan, and exercise program, do not blindly buy drugs, blood sugar fluctuations will accelerate the development of complications. Wishing you good health! h

1. Efficacy: Repaglitinide tablets can be used for type 2 diabetes with high blood sugar that cannot be effectively controlled by diet control and exercise. Among them, the main active ingredient repaglinide is a short-acting insulin secretagogue, which can reduce blood sugar levels by promoting the release of insulin from the pancreas.

This effect is dependent on the functioning cells in the islets. Therefore, loss of islet function or more severe type 1 diabetes is not suitable for this medicine.

2. Repaglinide tablets are a kind of oral preparation, and it is recommended to take this medicine 15 minutes before the main meal. The specific dosage should be determined according to the individual's condition and used under the guidance of Physician Huaiwuling. In the process of taking the drug, the experiment found that the patient may have the following adverse reactions:

Hypoglycemia (including anxiety, sweating, dizziness, hunger, difficulty concentrating, etc.); abdominal pain, diarrhea; Allergic reactions such as itching, rashes, hives, etc.

1.Hypoglycemia: These reactions are usually mild and can be easily corrected by giving carbohydrates. In more severe cases, glucose may be transfused.

2.Visual abnormalities are known to cause temporary visual abnormalities, especially at the beginning. There are very few cases of cases of repaglinide tablets** at the beginning of the occurrence of the above-mentioned visual abnormalities, but there are no cases in clinical trials where repaglinide tablets are discontinued because of this.

3.Gastrointestinal reactions such as abdominal pain, diarrhoea, nausea, vomiting, and constipation have been reported in gastrointestinal clinical trials. There was no difference in the frequency or severity of these symptoms compared with other oral hypoglycemic drugs.

4.Individual cases of liver enzyme system reported an increase in liver function enzyme index during the use of repaglinide tablets**. Most cases are mild and transient, and very few patients stop due to elevated enzyme levels**.

5.Allergic reactions can occur** allergic reactions such as itching, redness, hives. Due to the difference in chemical structure, there is no reason to suspect the possibility of cross-allergic reactions with sulfonylureas.

Itching may be caused by diabetes, of course, it is necessary to rule out impaired liver function, it is recommended to actively control blood sugar to improve itching, and if necessary, to regulate the nerves**.

Reply expert: Xinyang 154 Central Hospital - Department of Endocrinology and Hematology - Deputy Chief Physician Wang Lizheng.

View the original post

Diabetes requires lifelong **, and its ** effect largely depends on the initiative of the patient, all diabetic patients regardless of their condition, the first thing to adhere to is diet control, and secondly, for patients whose diet ** and physical exercise can not make blood sugar well controlled, they need to take drugs, or subcutaneous insulin**.

You don't want to continue taking medicine now because you feel that your symptoms are very mild or you don't have it in your book, so you have lost the motivation to stick to taking medicine, which is what we medical workers are most worried about.

In the process of diabetes, hypertension, tuberculosis, hepatitis B antiviral**, etc., patients do not have good compliance with long-term medication, and finally lead to the abandonment of pre-filming, recurrence of the disease, or more difficult **after**.

It is recommended that you do not stop taking the drug, once you are cautious about the complications of diabetes, it is not as simple as oral hypoglycemic drugs, and you may even need to inject diabetes subcutaneously every day to control the condition.

Once high blood sugar causes damage to the cardiovascular system and damage to the retina, it is irreparable.

It's not that I'm alarmist, just thinking about the potential dangers of interrupting ** and the foreseeable consequences, you shouldn't stop taking the drug without permission.

In the general patient group, repaglinide is used for patients who cannot effectively control blood sugar due to diet control, weight loss and exercise, and still have symptoms of diabetes. Like most other oral insulin-secreting hypoglycemic drugs, repaglinide can cause hypoglycemia. Combination with metformin increases the risk of hypoglycemia.

Glycemic control failure may occur when a patient is taking any oral hypoglycemic drug on a regular basis, such as fever, trauma, infection, or surgery. At this time, it is necessary to stop taking repaglinide and take a short course of insulin**. Oral hypoglycemic drugs may decrease with the prolongation of medication in most patients.

This can lead to an exacerbation of diabetes and a decrease in the effectiveness of medications. Unlike primary failure, which fails at the first dose, this phenomenon is secondary failure. Dose adjustment and adherence to diet and exercise should be considered until secondary failure is determined.

Repaglinide has not been studied in patients with hepatic insufficiency. It was also not studied in patients under 18 years of age or over 75 years of age. In frail or malnourished patients, initial and maintenance doses should be conservative and carefully adjusted to avoid hypoglycemia.

Hepatic insufficiency in special patient groups. At usual doses, patients with hepatic impairment may be exposed to higher concentrations of repaglinide and its metabolites compared with patients with normal liver function. Therefore, patients with liver impairment should use this product with caution.

The adjustment interval between dose adjustments should be prolonged to adequately assess the patient's response (see [Pharmacokinetics]). Renal insufficiency. Although repaglinide level is only weakly related to creatinine clearance, the total plasma clearance of this product is slightly reduced in patients with severe renal impairment.

Because of the increased sensitivity to insulin in diabetic patients with renal impairment, these patients should be cautious when increasing the dose (see [Pharmacokinetics]). Effects on driving and mechanical maneuvering abilityPatients may experience inattention and decreased consciousness due to hypoglycemia. This can lead to situations such as:

when driving or operating machinery). Patients should be instructed to take care to avoid hypoglycemia while driving. Particular attention should be paid to patients with decreased or lost consciousness when hypoglycaemia occurs, or in patients who have frequent hypoglycaemia.

In these cases, the patient's ability to drive safely should be considered first.

Meglitinides are benzoic acid derivatives, which are non-sulfonylurea insulin secretagogues, which have a short duration of action and are prandial blood glucose regulators, suitable for patients with high postprandial blood glucose. repaglinide does not have a significant effect on fasting blood sugar (resulting in high fasting blood sugar).

In general, the adverse reactions of meglitinide drugs are few and mild, mainly hypoglycemia, gastrointestinal disorders, allergic reactions, and abnormal liver function are only seen in individual patients and are mostly mild and transient.